Phase Forward | Tech | Seven Days | Vermont's Independent Voice

Seven Days needs your financial support!

Phase Forward 

Published September 24, 2008 at 3:05 p.m.

Phase Forward is a leading provider of integrated data collection and data-management solutions for clinical trials and drug safety. Its award-winning technology and global services are designed to enable life-sciences companies of all types and sizes to automate and integrate the management of their entire clinical development process — from study initiation and FDA submission through post-marketing studies. Phase Forward's products and services have been used in more than 10,000 clinical trials involving more than 1 million trial study participants at more than 250 life-sciences companies, medical-device firms, regulatory agencies and public-health organizations.

The Massachusetts-based company — with international headquarters in Maidenhead, U.K. — expanded its product offerings when it acquired Vermont's Green Mountain Logic last October. The Montpelier office is focused on the LabPas product suite, a groundbreaking software platform providing substantial improvements in quality, efficiency and speed for Phase I clinical drug trials and life-science laboratories.

Got something to say? Send a letter to the editor and we'll publish your feedback in print!

More By This Author

  • Find a Job, Make Connections and Learn About Local Innovation at the Vermont Tech Jam
  • Find a Job at Vermont Tech Jam Oct. 22

    Vermont is home to numerous innovative tech companies that make everything from underwater robots to battery-powered aircraft. Learn about them at the Vermont Tech Jam, an annual career and tech expo on Saturday, October 22 at Hula on the Burlington waterfront. This year's keynote presenters: Boston Scientific cofounder John Abele and Sarah Kalil, CEO of the Vermont-based CoreMap. (7D PROMO)
    • Sep 27, 2022
  • More »

About The Author

7D Staff


Comments are closed.

Since 2014, Seven Days has allowed readers to comment on all stories posted on our website. While we’ve appreciated the suggestions and insights, the time has come to shut them down — at least temporarily.

While we champion free speech, facts are a matter of life and death during the coronavirus pandemic, and right now Seven Days is prioritizing the production of responsible journalism over moderating online debates between readers.

To criticize, correct or praise our reporting, please send us a letter to the editor. Or send us a tip. We’ll check it out and report the results.

Online comments may return when we have better tech tools for managing them. Thanks for reading.

Keep up with us Seven Days a week!

Sign up for our fun and informative

All content © 2022 Da Capo Publishing, Inc. 255 So. Champlain St. Ste. 5, Burlington, VT 05401

Advertising Policy  |  Privacy Policy  |  Contact Us  |  About Us  |  Help
Website powered by Foundation